Lifecore Biomedical Net Worth

Lifecore Biomedical Net Worth Analysis

Lifecore Biomedical Target Price Consensus

Lifecore Biomedical Target Price Projection

Lifecore Biomedical's current and average target prices are 8.19 and 10.00, respectively. The current price of Lifecore Biomedical is the price at which Lifecore Biomedical is currently trading. On the other hand, Lifecore Biomedical's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Lifecore Biomedical and the information provided on this page.

Know Lifecore Biomedical's Top Institutional Investors

Note, although Lifecore Biomedical's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Lifecore Biomedical's market capitalization trends

The company currently falls under 'Small-Cap' category with a current market capitalization of 297.68 M.

Project Lifecore Biomedical's profitablity

The company has Profit Margin (PM) of (0.34) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.07) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.07.

Evaluate Lifecore Biomedical's management efficiency

Lifecore Biomedical has return on total asset (ROA) of (0.0311) % which means that it has lost $0.0311 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8358) %, meaning that it created substantial loss on money invested by shareholders. Lifecore Biomedical's management efficiency ratios could be used to measure how well Lifecore Biomedical manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Lifecore Biomedical's Non Currrent Assets Other are relatively stable compared to the past year. As of 07/08/2025, Other Assets is likely to grow to about 25.1 M, while Total Assets are likely to drop slightly above 248.7 M. Lifecore Biomedical time-series forecasting models is one of many Lifecore Biomedical's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Lifecore Biomedical's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Lifecore Biomedical Earnings Estimation Breakdown

The calculation of Lifecore Biomedical's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Lifecore Biomedical is estimated to be -0.035 with the future projection ranging from a low of -0.335 to a high of -0.33. Please be aware that this consensus of annual earnings estimates for Lifecore Biomedical is based on EPS before non-recurring items and includes expenses related to employee stock options.

Lifecore Biomedical Earnings Projection Consensus

Lifecore Biomedical Earnings History

Earnings estimate consensus by Lifecore Biomedical analysts from Wall Street is used by the market to judge Lifecore Biomedical's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Lifecore Biomedical's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods. As of 07/08/2025, Retained Earnings is likely to grow to about (181.9 M) As of 07/08/2025, Common Stock Shares Outstanding is likely to drop to about 26.4 M. In addition to that, Net Loss is likely to grow to about (87.4 M).

Hype Prediction Low Estimated High 5.04 8.15 11.26 Details

Intrinsic Valuation Low Real High 5.16 8.27 11.38 Details

3 Analysts Consensus Low Target High 9.10 10.00 11.10 Details

Earnings Estimates (0) Low Projected EPS High -0.34 -0.04 -0.33 Details

Note that many institutional investors and large investment bankers can move markets due to the volume of Lifecore assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Lifecore Biomedical. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Lifecore Biomedical's stock price in the short term.

Lifecore Biomedical Earnings per Share Projection vs Actual

Actual Earning per Share of Lifecore Biomedical refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Lifecore Biomedical predict the company's earnings will be in the future. The higher the earnings per share of Lifecore Biomedical, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Lifecore Biomedical Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Lifecore Biomedical, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Lifecore Biomedical should always be considered in relation to other companies to make a more educated investment decision.

Lifecore Quarterly Analyst Estimates and Surprise Metrics

Lifecore Biomedical Corporate Management

Additional Tools for Lifecore Stock Analysis